Grocery, prescription and vaccination services will be brought to residents’ doorsteps in support of community nutrition, health and wellness
BOISE, Idaho, September 15, 2022--(BUSINESS WIRE)--Albertsons Companies, Inc. (NYSE: ACI) announced today a new partnership with WinnCompanies – a leader in affordable, mixed-income and market-rate housing – to bring essential services directly to more than 133,000 residents across 520 properties nationally. The collaboration will provide grocery, prescription and vaccination resources to seniors and families, reducing accessibility barriers and further fostering the company’s commitment to support the health and well-being of the communities it serves.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005185/en/
Albertsons Companies, Inc. announced a new partnership with WinnCompanies to provide grocery, prescription and vaccination resources directly to more than 133,000 residents across 520 properties nationally. Courtesy: Albertsons Companies
"We recognize that many people in our communities face challenges that prevent them from shopping in our stores," said Omer Gajial, Chief Digital Officer and EVP of Health at Albertsons Cos. "As a neighborhood grocer, we’re privileged to partner with WinnCompanies to make nutrition, wellness and pharmacy services more accessible and convenient for WinnCompanies’ residents."
This long-term partnership is a first in providing WinnCompanies’ residents with a means for fulfilling grocery, prescription and vaccination needs through a single provider, and driving impact through WinnCompanies Connected Communities initiative that focuses on collaborative strategies for measurable and positive outcomes.
The services being provided on an ongoing basis will include prescription drop-off and mail delivery, grocery delivery and on-site immunizations by Albertsons Cos.’ pharmacy associates. Residents will be able to receive the recommended vaccinations they need to stay up to date including the COVID-19 bivalent vaccines from Moderna and Pfizer-BioNTech, flu vaccines and other key immunizations such as shingles, pneumonia, tetanus and hepatitis A and B.
In addition to the on-site clinics, residents also have access to care at Albertsons Cos. pharmacies, including those at Safeway, Albertsons, Shaw’s, Star Market and Jewel-Osco stores across the country. Most pharmacies offer convenient evening and weekend hours and are staffed to accommodate short wait times and "walk-in" appointments. Pharmacists are also available to discuss clinical-related questions to assist customers in making informed healthcare decisions.
To make the digital shopping experience more equitable, EBT SNAP benefits were recently integrated into Albertsons Cos.’ websites and apps for same-day grocery delivery and curbside pickup orders, ensuring that families and individuals who rely on these benefits have greater access to nutritious food.
"This collaboration with Albertson Cos. reinforces our commitment to have a positive and lasting impact on the quality of life of the residents at our apartment communities," said Trevor Samios, Senior Vice President of Connected Communities at WinnCompanies. "We’re grateful to find a partner who shares this mission and is willing to join us in committing important resources to the health and safety of thousands of individuals and families across the country."
Both Albertsons Cos. and WinnCompanies have a long history of forming partnerships with the aim of solving longstanding food and healthcare inequalities, prompting a pilot partnership program in Massachusetts in late 2021. Based on initial success, the program has now expanded to all WinnCompanies communities where Albertsons Cos. serves including those in California, District of Columbia, Illinois, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Texas and Virginia.
For more information on Albertsons Cos.’ benefits for SNAP customers, visit here.
For more information on Albertsons Cos., Inc., visit here.
For more information on WinnCompanies, visit here.
Albertsons Companies is a leading food and drug retailer in the United States. As of June 18, 2022, the Company operated 2,273 retail food and drug stores with 1,720 pharmacies, 402 associated fuel centers, 22 dedicated distribution centers and 19 manufacturing facilities. The Company operates stores across 34 states and the District of Columbia with 24 banners including Albertsons, Safeway, Vons, Jewel-Osco, Shaw's, Acme, Tom Thumb, Randalls, United Supermarkets, Pavilions, Star Market, Haggen, Carrs, Kings Food Markets and Balducci's Food Lovers Market. The Company is committed to helping people across the country live better lives by making a meaningful difference, neighborhood by neighborhood. In 2021, along with the Albertsons Companies Foundation, the Company contributed nearly $200 million in food and financial support, including approximately $40 million through our Nourishing Neighbors Program to ensure those living in our communities have enough to eat.
WinnCompanies is an award-winning, national owner, developer and manager of high-impact affordable, middle income, mixed-income, market rate and military housing communities. Founded in Boston in 1971 and supported by 3,800 team members in 23 states and the District of Columbia, WinnCompanies is one of the nation’s leading multi-family housing managers with 103,000 residential and military apartment homes under management. It is a leading manager of affordable housing and privatized U.S. military housing in the United States. The company owns 120 apartment communities in 11 states and the District of Columbia.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005185/en/
Jessica Keener media@albertsons.com
The sex lives of constipated scorpions, cute ducklings with an innate sense of physics, and a life-size rubber moose may not appear to have much in common, but they all inspired the winners of this year’s Ig Nobels, the prize for comical scientific achievement. Held less than a month before the actual Nobel Prizes are announced, Thursday's 32nd annual Ig Nobel prize ceremony was for the third year in a row a prerecorded affair webcast on the Annals of Improbable Research magazine's website. The winners, honored in 10 categories, also included scientists who found that when people on a blind date are attracted to each other, their heart rates synchronize, and researchers who looked at why legal documents can be so utterly baffling, even to lawyers themselves.
Stéphane Bancel discusses the company’s latest Covid shot and prospects for using mRNA in seasonal flu vaccines and personalized treatments for cancer
Omeros Corp (NASDAQ: OMER) reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC). Narsoplimab showed the largest reduction in mortality risk to date across all drugs reported from the I-SPY COVID Trial. The company said that in approximately half of the patients died in the narsoplimab group, and narsoplimab was not given or was prematurely stopped, with those patients dying 9 to 35 days later. Omeros adds that despite narso
Investors have lost patience with the slow-paced clinical trials of genetic therapies, and some are using the upbeat news to exit Intellia and peers.
Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.
Gilead Sciences Inc (NASDAQ: GILD) announced updates to the World Health Organization's (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury (remdesivir) for severe COVID-19. WHO continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization. The WHO conditional recommendation is mainly driven by the final results of the WHO-sponsored SOLIDARITY study, which showed a statistically significant 17% lowe
In that spirit, let's examine two healthcare stocks that seem to have the tools to provide solid returns over the long term: Eli Lilly (NYSE: LLY) and Teladoc Health (NYSE: TDOC). Eli Lilly seems to excel in both areas. Take one of the company's most recent approvals: Mounjaro, a therapy used to control blood glucose levels in patients with type 2 diabetes.
Lumakras had mixed results in a closely watched clinical trial comparing the drug to docetaxel. Analysts wonder if Mirati Therapeutics' drug will do better.
Based on positive top-line data from phase III on its pentavalent meningococcal vaccine, Pfizer (PFE) intends to submit a regulatory application to the FDA seeking approval by year-end.
Intellia Therapeutics said two of its experimental Crispr treatments produced positive results in early-stage trials.
A labor shortage at a pharmaceutical company along with increased demand left Adderall on back-order at many pharmacies across the country.
The latest clinical news from Bristol Myers Squibb (NYSE: BMY) was quite encouraging, sufficient to drive the pharmaceutical giant's stock higher on an otherwise uninspired day for the broader stock market. Bristol Myers Squibb's share price experienced a nearly 2% bump, a notably better showing than the S&P 500 index's more than 1% decline. Bristol Myers Squibb's good news from the lab was that its enduringly popular cancer drug Opdivo did quite well in its latest round of testing.
Updated COVID-19 boosters targeting specific omicron strains of the coronavirus are now available. Here are the most common side effects you might experience.
The following two healthcare stocks look like great buys for investors seeking to collect both above-average income and increase wealth. The good news for cancer patients is that Merck's (NYSE: MRK) cancer drug called Keytruda is approved in the U.S. to treat 19 different forms of the disease. Looking out over the long term, Merck's pipeline is just as strong as its existing products.
Eloxx Pharmaceuticals' (ELOX) phase II combination study evaluating pipeline candidate ELX-02 in cystic fibrosis fails to achieve statistical significance in efficacy endpoints.
"If we are forcing millions of people into this world, we as a society — whether you are right, whether you are left, whether you are 'pro-life' or not — it doesn't matter. You will all suffer the consequences of a crowded, broken political, healthcare, and education system."View Entire Post ›
Pharmaceutical giant Merck (NYSE: MRK) delivered outstanding second-quarter results in July, largely driven by its mainstay cancer blockbuster, Keytruda. The company reported 28% year-over-year total revenue growth and continues to develop Keytruda for new cancer indications. Under the radar, however, Keytruda returned some bad news in three separate late-stage clinical trials this summer.
In June, a Dallas area doctor who was feeling unwell wanted to use a saline IV bag she had gotten from her work to try to rehydrate. She tapped it into her veins while at home. Minutes later, she suffered a major medical event and died, court records say. Now, Raynaldo Rivera Ortiz Jr., an anesthesiologist at her surgical facility, faces federal charges for allegedly tampering with IV bags in a way that resulted in the death of his colleague as well as several other cardiac emergencies, accordin
Let’s be honest: When it comes to calorie-torching and strength-training workouts, squats really get the job done. This exercise can be performed in many different variations, activating numerous muscle groups. With squats, you will definitely be feeling the burn. One of the most common questions ...
How do you fix a forgetful memory? Neurologist shares brain exercises to keep memory sharp, including reading fiction, cooking from recipes and playing games.